In estrogen-sensitive breast cancer, the expression of GPR158 is down-regulated following the withdrawal of estrogen or the use of estrogen antagonists (Salazar et al., 2011), suggesting that GPR158 may be a novel biomarker for the prognosis of ovarian carcinoma and breast cancer. Here, GPR158 is linked to breast carcinoma.